ScreenerHero

GELSGelteq Limited Ordinary Shares

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · gelteq.com
0.5628USDMkt Cap: 6.03M $P/E: —

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs,…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap6.03M $
Enterprise Value11.32M $
Revenue (TTM)471.80K $
Gross Profit356.40K $
Net Income (TTM)-6.65M $
Revenue/Share0.0460 USD
Last Price0.5628 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees7
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.20
EV/Revenue24.00
P/S12.66
P/B0.62
EPS (TTM)-0.52
EPS (Forward)—
52W Range
0.536650% of range0.5890
52W High0.5890 USD
52W Low0.5366 USD
Profitability
Gross Margin75.54%
Oper. Margin-1985.28%
EBITDA Margin0.00%
Profit Margin-4011.86%
ROE-42.05%
ROA-30.94%
Growth
Revenue Growth48.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.01M $
CapEx (TTM)642.23K $
FCF Margin-1007.19%
FCF Yield-78.83%
Net Debt5.10M $
Net Debt/EBITDA-0.99
Balance Sheet
Debt/Equity0.27
Current Ratio0.09
Quick Ratio0.07
Book Value/Sh0.9027 USD
Cash/Share0.0010 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.10.71M
Float5.15M
Insiders47.53%
Institutions1.03%
Short Interest
Short Ratio0.3d
Short % Float0.48%
Short % Out.0.32%
Shares Short33.88K
Short (prev mo.)167.46K
Technical
SMA 500.6656 (-15.4%)
SMA 2000.7654 (-26.5%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)15.38K
Avg Vol (10d)24.59K
Technical Indicators
RSI (14)47.0
MACD-0.0158
MACD Signal-0.0175
MACD Hist.+0.0018
BB Upper0.6242 USD
BB Middle0.5663 USD
BB Lower0.5084 USD
BB Width20.44%
ATR (14)0.0696 USD
Vol Ratio (20d)0.34x